In silico identification and analysis of potential inhibitors for acid phosphatase, HppA from Helicobacter pylori
-
Published:2023-08-08
Issue:9
Volume:36
Page:
-
ISSN:0952-3499
-
Container-title:Journal of Molecular Recognition
-
language:en
-
Short-container-title:J of Molecular Recognition
Author:
Sisodia Rinki1,
Mazumdar Pooja Anjali2,
Madhurantakam Chaithanya1ORCID
Affiliation:
1. Structural and Molecular Biology Laboratory (SMBL), Department of Biotechnology TERI School of Advanced Studies (TERI SAS) New Delhi India
2. Independent Researcher New Delhi India
Abstract
AbstractHelicobacter pylori is the most common cause of gastric ulcers and is associated with gastric cancer. The enzyme HppA of class C nonspecific acid phosphohydrolases (NSAPs) of H. pylori plays a crucial role in the electron transport chain. Herein, we report an in silico homology model of HppA consisting of a monomeric α + β model. A high throughput structure‐based virtual screening approach yielded potential inhibitors against HppA with higher binding energies. Further analyses of molecular interaction maps and protein–ligand fingerprints, followed by molecular mechanics‐generalized Born surface area (MM‐GBSA) end point binding energy calculations of docked complexes, resulted in the detection of top binders/ligands. Our investigations identified potential substrate‐competitive small molecule inhibitors of HppA, with admissible pharmacokinetic properties. These molecules may provide a starting point for developing novel therapeutic agents against H. pylori.
Funder
Council of Scientific and Industrial Research, India
Indian Council of Medical Research
Subject
Molecular Biology,Structural Biology
Reference86 articles.
1. Helicobacter pylori Oncogenicity: Mechanism, Prevention, and Risk Factors
2. Schistosomes, liver flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 7–14 June 1994;IARC Monogr Eval Carcinog Risks Hum,1994
3. Biological agents. Volume 100 B. A review of human carcinogens;IARC Working Group on the Evaluation of Carcinogenic Risks to Humans;IARC Monogr Eval Carcinog Risks Hum,2012
4. The incidence of Helicobacter pylori infection;Parsonnet J;Aliment Pharmacol Ther,1995
5. Helicobacter pylori: A Brief History of a Still Lacking Vaccine